370
Views
37
CrossRef citations to date
0
Altmetric
Tryptamine and Phenethylamine Use

“Research Chemicals”: Tryptamine and Phenethylamine Use Among High-Risk Youth

, , &
Pages 389-402 | Published online: 03 Jul 2009

References

  • Australian Bureau of Criminal Intelligence (ABCI). Australian Illicit Drug Report 2000–01. Commonwealth of Australia, Canberra 2002
  • Biernacki P., Waldorf D. Snowball: Problems and techniques of chain referral sampling. Sociological Methods and Research 1981; 10: 141–163
  • Carmo H., Hengstler J. G., de Boer D., Ringel M., Remiao F., Carvalho F., et al. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): Analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 2005; 206(1)75–89
  • Check E. The ups and downs of ecstasy. Nature 2004; 429: 126–128
  • Clatts M. C., Rees Davis W., Atillasoy A. Hitting a moving target: The use of ethnographic methods in the development of sampling strategies for the evaluation of AIDS outreach programs for homeless youth in New York City. The collection and interpretation of data from hidden populations, E. Lambert. US Department of Health and Human Services, Rockville, MD 1995, (NIDA Research Monograph 98)
  • Des Jarlais D., Perlis T., Settembrino J. The use of electronic debit cards in longitudinal data collection with geographically mobile drug users. Drug and Alcohol Dependence 2005; 77(1)1–5
  • Drug Enforcement Administration. Microgram Bulletin 2003; 36(5), Washington, DC: Author
  • Drug Enforcement Administration. Microgram Bulletin 2005; 38(3), Washington, DC: Author
  • Griffiths R. R., Richards W. A., McCann U., Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance [Electronic version]. Psychopharmacology 2006; 187: 268–283
  • Halpern J. H. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology Therapeutics 2004; 102(2)131–138
  • Halpern J. H., Pope H. G., Jr. Do hallucinogens cause residual neuropsychological toxicity?. Drug and Alcohol Dependence 1999; 53(3)247–256
  • Halpern J. H., Pope H. G., Jr. Hallucinogens on the Internet: A vast new source of underground drug information. American Journal of Psychiatry 2001; 158(3)481–483
  • Hathazi D., Lankenau S. E., Sanders B., Jackson-Bloom J. The Normalization of polydrug use amongst homeless traveler youth. Paper presented at the American Public Health Association 133rd Annual Meeting, Philadelphia, December, 2005
  • Hyde J. From home to street: Understanding young people's transitions into homelessness. Journal of Adolescence 2005; 28(2)171–183
  • Jacob M. S., Presti D. E. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine. Medical Hypotheses 2005; 64(5)930–937
  • Jansen K. L. R. Ketamine: Dreams and realities. Multidisciplinary Association for Psychedelic Studies, Sarasota, FL 2001
  • Kalant H. The pharmacology and toxicology of “ecstasy”: (MDMA) and related drugs. Canadian Medical Association Journal 2001; 165(7)917–928
  • Kikura-Hanajiri R., Hayashi M., Saisho K., Goda Y. Simultaneous determination of nineteen hallucinogenic tryptamines/beta-calbolines and phenethylamines using gas chromatography-mass spectrometry and liquid chromatography-electrospray ionisation-mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2005; 825(1)29–37
  • Laks S., Pelander A., Vuori E., Ali-Tolppa E., Sippola E., Ojanpera I. Analysis of street drugs in seized material without primary reference standards. Analytical Chemistry 2004; 76(24)7375–7379
  • Lankenau S. E. On ketamine: In and out of the K hole. Drugs, clubs and young people: Sociological and public health perspective, B. Sanders. Ashgate, Aldershot, UK 2006
  • Lankenau S. E., Clatts M. C. Patterns of polydrug use among ketamine injectors in New York City. Substance Use Misuse 2005; 40: 1381–1397
  • Lankenau S. E., Sanders B. Patterns and frequencies of ketamine use in New York City. Journal of Psychoactive Drugs 2007
  • Lankenau S. E., Sanders B., Jackson-Bloom J., Hathazi S., Alarcon E., Tortus S., Clatts M. Ketamine injection initiation among young injection drug users (IDUs) in three U.S. cities. Drug and Alcohol Dependence 2007; 87: 183–193
  • McCandless D. Goodbye ecstasy, hello 5-Meo-DMT: New designer drugs are just a click away. February 16, 2004, http://www:guardian.co.uk The Guardian (Electronic Version) Available from
  • McKenna D. J. Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacology and Therapeutics 2004; 102(2)111–129
  • Measham F. Play space: Historical and socio-cultural reflections on drugs, licensed leisure locations, commercialization and control. International Journal of Drug Policy 2004; 15: 337–345
  • Muller A. A. New drugs of abuse update: Foxy methoxy. Journal of Emergency Nursing 2004; 30(5)507–508
  • Nichols D. E. Hallucinogens. Pharmacology and Therapeutics. 2004; 101: 131–181
  • Penrod J., Preston D. B., Cain R. E., Starks M. A discussion of chain referral as a method for sampling hard-to-reach populations. Journal of Transcultural Nursing 2003; 14: 100–107
  • Rushkoff D. Cyberia: Life in the trenches of hyperspace. Clinamen Press, Manchester, UK 1994
  • Sanders B. Young people, clubs and drugs. Drugs, clubs and young people: Sociological and public health perspectives, B. Sanders. Ashgate, Aldershot, UK 2006; 1–12
  • Sewell R. A., Halpern J. H., Pope H. G., Jr. Response of cluster headache to psilocybin and LSD. Neurology 2006; 66(12)1920–1922
  • Sessa B. Can psychedelics have a role in psychiatry once again?. British Journal of Psychiatry 2005; 186: 457–458
  • Shulgin A., Shulgin A. PiHKAL (phenethylamines I have known and loved). Transform Press, Berkeley 1991
  • Shulgin A., Shulgin A. TiHKAL (tryptamines I have known and loved): The continuation. Transform Press, Berkeley 1997
  • Tanaka E., Kamata T., Katagi M., Tsuchihashi H., Honda K. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy [Electronic version]. Forensic Science International 2006; 163: 152–154
  • Vastag B. Addiction research: Ibogaine therapy: A “vast, uncontrolled experiment.”. Science 2005; 308(5720)345–346
  • Watters J. K., Biernacki P. Targeted sampling: Options and considerations for the study of hidden populations. Social Problems 1989; 36: 416–430
  • Wilson J. M., McGeorge F., Smolinske S., Meatherall R. A foxy intoxication. Forensic Science International 2005; 148(1)31–36
  • Winstock A. R., Wolff K., Ramsey J. Ecstasy pill testing: harm minimization gone too far?. Addiction 2001; 96(8)1139–1148
  • Yacoubian G. S., Jr., Miller S., Pianim S., Kunz M., Orrick E., Link T., et al. Toward an ecstasy and other club drug (EOCD) prevention intervention for rave attendees. Journal of Drug Education 2004; 34(1)41–59
  • Zinberg N. E. Drug, set, and setting: The basis for controlled intoxicant use. Yale University Press, New Haven 1984

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.